Literature DB >> 28596282

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Luca Laurenti1, Idanna Innocenti2, Francesco Autore2, Stefania Ciolli3, Francesca Romana Mauro4, Donato Mannina5, Giovanni Del Poeta6, Giovanni D'Arena7, Massimo Massaia8, Marta Coscia9, Stefano Molica10, Gabriele Pozzato11, Dimitar G Efremov12, Barbara Vannata2, Roberto Marasca13, Pietro Galieni14, Antonio Cuneo15, Sonia Orlando16, Alfonso Piciocchi16, Riccardo Boncompagni3, Donatella Vincelli17, Anna Marina Liberati18, Filomena Russo19, Robin Foá4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28596282      PMCID： PMC5685238          DOI： 10.3324/haematol.2016.156901

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

3.  Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale.

Authors:  M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds
Journal:  Psychiatry Res       Date:  1992-03       Impact factor: 3.222

4.  Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

Authors:  Robin Foà; Ilaria Del Giudice; Antonio Cuneo; Giovanni Del Poeta; Stefania Ciolli; Francesco Di Raimondo; Francesco Lauria; Emanuele Cencini; Gian Matteo Rigolin; Agostino Cortelezzi; Francesco Nobile; Vincenzo Callea; Maura Brugiatelli; Massimo Massaia; Stefano Molica; Livio Trentin; Rita Rizzi; Giorgina Specchia; Francesca Di Serio; Lorella Orsucci; Achille Ambrosetti; Marco Montillo; Pier Luigi Zinzani; Felicetto Ferrara; Fortunato Morabito; Maria Angela Mura; Silvia Soriani; Nadia Peragine; Simona Tavolaro; Silvia Bonina; Marilisa Marinelli; Maria Stefania De Propris; Irene Della Starza; Alfonso Piciocchi; Alessandra Alietti; Eva Josephine Runggaldier; Enrica Gamba; Francesca Romana Mauro; Sabina Chiaretti; Anna Guarini
Journal:  Am J Hematol       Date:  2014-02-18       Impact factor: 10.047

5.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

6.  First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.

Authors:  Barbara F Eichhorst; Raymonde Busch; Stephan Stilgenbauer; Martina Stauch; Manuela A Bergmann; Matthias Ritgen; Nicole Kranzhöfer; Robert Rohrberg; Ulrike Söling; Oswald Burkhard; Anne Westermann; Valentin Goede; Carmen D Schweighofer; Kirsten Fischer; Anna-Maria Fink; Clemens M Wendtner; Günter Brittinger; Hartmut Döhner; Bertold Emmerich; Michael Hallek
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

Review 7.  Targeted therapies for CLL: Practical issues with the changing treatment paradigm.

Authors:  Nitin Jain; Susan O'Brien
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

8.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

Review 9.  Treatment of elderly patients with chronic lymphocytic leukemia.

Authors:  Barbara Eichhorst; Valentin Goede; Michael Hallek
Journal:  Leuk Lymphoma       Date:  2009-02

10.  Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience.

Authors:  Luca Laurenti; Barbara Vannata; Idanna Innocenti; Francesco Autore; Francesco Santini; Nicola Piccirillo; Tommaso Za; Silvia Bellesi; Sara Marietti; Simona Sica; Dimitar G Efremov; Giuseppe Leone
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-05-02       Impact factor: 2.576
View more
  3 in total

Review 1.  Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.

Authors:  Thomas E Lew; Mary Ann Anderson; John F Seymour
Journal:  Cancer Drug Resist       Date:  2020-05-23

2.  Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.

Authors:  Alberto Fresa; Francesco Autore; Alfonso Piciocchi; Gioacchino Catania; Andrea Visentin; Annamaria Tomasso; Marina Moretti; Candida Vitale; Annalisa Chiarenza; Francesca Morelli; Paolo Sportoletti; Roberto Marasca; Giuseppe Sapienza; Annarosa Cuccaro; Roberta Murru; Alessandro Sanna; Caterina Patti; Ilaria Angeletti; Marta Coscia; Livio Trentin; Daniela Pietrasanta; Idanna Innocenti; Luca Laurenti
Journal:  Blood Adv       Date:  2022-07-12

3.  Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.

Authors:  Antonio Cuneo; Anthony R Mato; Gian Matteo Rigolin; Alfonso Piciocchi; Massimo Gentile; Luca Laurenti; John N Allan; John M Pagel; Danielle M Brander; Brian T Hill; Allison Winter; Nicole Lamanna; Constantine S Tam; Ryan Jacobs; Frederick Lansigan; Paul M Barr; Mazyar Shadman; Alan P Skarbnik; Jeffrey J Pu; Alison R Sehgal; Stephen J Schuster; Nirav N Shah; Chaitra S Ujjani; Lindsey Roeker; Ester Maria Orlandi; Atto Billio; Livio Trentin; Martin Spacek; Monia Marchetti; Alessandra Tedeschi; Fiorella Ilariucci; Gianluca Gaidano; Michael Doubek; Lucia Farina; Stefano Molica; Francesco Di Raimondo; Marta Coscia; Francesca Romana Mauro; Javier de la Serna; Angeles Medina Perez; Isacco Ferrarini; Giuseppe Cimino; Maurizio Cavallari; Rosalba Cucci; Marco Vignetti; Robin Foà; Paolo Ghia
Journal:  Cancer Med       Date:  2020-09-24       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.